What this Trial Is About

Researchers are evaluating the safety and effectiveness of Envlo and Envlomet SR tablets in adults with type 2 diabetes who also have hypertension or dyslipidemia. This is a multi-center, non-interventional observational study tracking patients over 24 weeks in real-world clinical settings. The study includes patients who are already taking or are scheduled to start taking these medications. Participants will receive either Envlo tablet 0.3 mg or Envlomet SR tablet containing 0.3 mg Envlo and 1,000 mg Metformin, based on their doctor's decision. The study does not require any additional treatments or visits beyond routine care. Data collection will include medical records and measurements taken during regular clinical visits over the 24-week period. Throughout the study, researchers will gather information on participants' demographics, body measurements, vital signs, and medical records. They will assess how well patients achieve blood glucose, LDL cholesterol, and blood pressure targets at 24 weeks. There are no mandatory extra visits or tests required, and participant safety and treatment effects will be monitored in the usual clinical environment.

Evaluation of Enavogliflozin's Efficacy and Safety in Type II Diabetes With Hypertension or Dyslipidemia